Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer-Reference-Cited by-同舟云学术

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Published:2019-11 Issue:11 Volume:30 Page:1842
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hortobagyi G.N.,Stemmer S.M.,Burris H.A.,Yap Y.S.,Sonke G.S.,Paluch-Shimon S.,Campone M.,Petrakova K.,Blackwell K.L.,Winer E.P.,Janni W.,Verma S.,Conte P.,Arteaga C.L.,Cameron D.A.,Mondal S.,Su F.,Miller M.,Elmeliegy M.,Germa C.,O’Shaughnessy J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz215/29153736/mdz215.pdf

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer;Future Oncology;2024-07-29

3. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials;Asia-Pacific Journal of Clinical Oncology;2024-06-16

4. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers;International Journal of Molecular Sciences;2024-05-06

5. Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method;Therapeutic Drug Monitoring;2024-02-06